Return to homepagePandemic Pact

Re-purposing current drugs to treat COVID-19

  • Funded by UK Research and Innovation (UKRI)
  • Total publications:0 publications

Grant number: C19-IUC-222

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    UK Research and Innovation (UKRI)

  • Principal Investigator

    Karim Labib

  • Research Location

    United Kingdom

  • Lead Research Institution

    MRC Protein Phosphorylation and Ubiquitylation Unit at the University of Dundee

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

We are developing tests to find out whether existing drugs could quickly be repurposed to treat COVID 19. As part of a collaboration with the Francis Crick institute in London, we are developing tests for drugs that might inhibit two of the enzymes of the SARS-CoV-2 virus: one called Nsp15 (an RNase) and another called Nsp14 (a methyltransferase)